Buspirone, marketed as Buspar, a nonbenzodiazepine and generally nonsedating anxiolytic, was the first prominent anxiolytic introduced after the benzodiazepines. Its antianxiety effects are believed to be secondary to its acting as a partial agonist of the 5-HT1A receptor. Buspirone is as effective as diazepam and superior to placebo in double-blind trials involving anxious outpatients (Schatzberg et al. 2003). The parent drug is metabolized by CYP3A4 while its metabolite is metabolized by CYP2D6. Important drug